

DcR1 Antibody

DcR1 (ED): TRAIL-R3, TRID, LIT

CATALOG NO.: 2179

BACKGROUND:

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT (2-7) and DcR2/TRAIL-R4/TRUNDD (8-10). DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycopospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines (2,3). Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis (2,3).

SOURCE:

Rabbit polyclonal DcR1 antibody was raised against a peptide corresponding to amino acids in an extracellular domain (ED) of human DcR1 precursor (2-3).

APPLICATION:


DcR1 antibody can be used for detection of DcR1 by Western blot at 0.5 – 1 µg/ml. (Optimal dilution should be determined by user.) HeLa cell lysate can be used as positive control and an approximate 65 kDa band can be detected (6). DcR1 antibody is human, mouse, and rat reactive. **For research use only.**

STORAGE:


DcR1 antibody is supplied as chromatography purified IgG, in PBS containing 0.02% sodium azide. Store at -20°C. Stable for one year at 2-8°C.

RELATED PRODUCTS:

Blocking peptide, Catalog No. **2179P**.
HeLa Cell Lysate, Catalog No. **1201**.
DR4 Antibody (CT), Catalog No. **1139**.
DR5 Antibody (CT), Catalog No. **2019**.



Immunocytochemistry of DcR1 in HeLa cells with DcR1 antibody at 10 µg/ml.



REFERENCES:

1. Pan G, O'Rourke K, Chinnaiyan et al. The receptor for the cytotoxic ligand TRAIL. *Science* 1997; 276:111-3.
2. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science* 1997; 277:815-8.
3. Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 1997; 277:818-21.
4. Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. *J. Exp. Med.* 1997; 186:1165-70.
5. MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J. Bio.Chem.* 1997; 272:25417-20.
6. Schneider P, Bodmer JL, Thome M, et al. Characterization of two receptors for TRAIL. *FEBS Lett.* 1997; 416:329-34.
7. Mongkolsapaya J, Cowper AE, Xu XN, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. *J. Immunol.* 1998; 160:3-6.
8. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr. Biol.* 1997; 7:1003-6.
9. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity* 1997; 7:813-20.
10. Pan G, Ni J, Yu G, et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. *FEBS. Lett.* 1998; 424:41-5. (RD0606)